In Merck Sharp & Dohme, Inc. v. Albrecht, 2019 WL 2166393 (U.S. May 20, 2019), the Supreme Court answered two significant questions governing the litigation of the implied federal preemption defense in prescription drug product liability cases: (1) procedurally, the ultimate determination of whether a claim is preempted is to be answered by the court, … Continue reading New Clarity on "Clear Evidence": Adjudication of Implied Preemption Defenses in Prescription Drug Product Liability Cases →